The role of cytochrome P450 in antiretroviral drug interactions

• KRIKORIAN SA, RUDORF DC: Drug–drug interactions and hiv therapy: what should pharmacists know? J. Pharm. Pract. (2005) 18:278-294.
   Google Scholar
• DE MAAT MMR, EKHART GC, HUITEMA ADR et al.: Drug interactions between antiretroviral drugs and comedicated agents. Clin. Pharmacokinet. (2003) 42:223-282.
   PubMed Web of Science ®Google Scholar
• ERNEST CS II, HALL SD, JONES DR: Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther. (2005) 312:583-591.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE LL, GREENBLATT DJ, GRASSI JM et al.: Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. (1998) 38:106-111.
   PubMed Web of Science ®Google Scholar
• GRANFORS MT, WANG JS, KAJOSAARI LI et al.: Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin. Pharmacol. Toxicol. (2006) 98:79-85.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE LL, GREENBLATT DJ, DUAN SX et al.: Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J. Pharm. Sci. (1998) 87:1184-1189.
   PubMed Web of Science ®Google Scholar
• YEH RF, GAVER VE, PATTERSON KB et al.: Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J. AIDS (2006) 42:52-60.
   PubMed Web of Science ®Google Scholar
• FLEXNER C: Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu. Rev. Pharmacol. Toxicol. (2000) 40:649-674.
   PubMed Web of Science ®Google Scholar
• GERBER JG: Using pharmacokinetics to optimize antiretroviral drug–drug interactions in the treatment of human immunodeficiency virus infection. Clin. Infect. Dis. (2000) 30:S123-S129.
   PubMed Web of Science ®Google Scholar
• ZELDIN RK, PETRUSCHKE RA: Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. (2004) 53:4-9.
   PubMed Web of Science ®Google Scholar
• BOFFITO M, ARNAUDO I, RAITERI R et al.: Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS (2003) 16:2081-2083.
   Web of Science ®Google Scholar
• CVETKOVIC RS, GOA KL: Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs (2003) 63:769-802.
   PubMed Web of Science ®Google Scholar
• GOUJARD C, VINCENT I, MEYNARD JL et al.: Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. (2003) 47:118-123.
   PubMed Web of Science ®Google Scholar
• TABURET AM, PIKETTY C, CHAZALLON C et al.: Interactions between atazanavir–ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48:2091-2096.
   PubMed Web of Science ®Google Scholar
• MURPHY RL, SOMMADOSSI JP, LAMSON M et al.: Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J. Infect. Dis. (1999) 179:1116-1123.
   PubMed Web of Science ®Google Scholar
• CHEN J, RAYMOND K: Roles of rifampicin in drug–drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann. Clin. Microbiol. Antimicrob. (2006) 5:3.
   PubMedGoogle Scholar
• BURMAN WJ, GALLICANO K, PELOQUIN C: Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus–related tuberculosis. Clin. Infect. Dis. (1999) 28:413-430.
   Google Scholar
• BENEDEK IH, JOSHI A, FISKE WD et al.: Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers [Abstract no 42280]. In: Conference Record of the 12th World AIDS Conference. Marathon Multimedia, Geneva, Switzerland (1998):829.
   Google Scholar
• Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. MMWR (2000) 49:185-189.
   PubMedGoogle Scholar
• BENEDECK IH, FISKE WD, WHITE SJ et al.: Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers. Clin. Infect. Dis. (1998) 27:1008 (Abstract).
   Google Scholar
• BORIN MT, CHAMBERS JH, CAREL BJ et al.: Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin. Pharmacol. Ther. (1997) 61:544-553.
   PubMed Web of Science ®Google Scholar
• BORIN MT, CHAMBERS JH, CAREL BJ et al.: Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res. (1997) 35:53-63.
   PubMed Web of Science ®Google Scholar
• MALDONADO S, LAMSON M, GIGLIOTTI M et al.: Pharmacokinetic (PK) Interaction between Nevirapine (NVP) and Rifabutin (RFB). In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents Chemotherapy, San Francisco, CA, USA, 26 – 29 September (1999):abstract no. 341.
   Google Scholar
• NIEMI M, BACKMAN JT, FROMM MF et al.: Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. (2003) 42:819-850.
   PubMed Web of Science ®Google Scholar
• JUSTESEN US, ANDERSEN AB, KLITGAARD NA et al.: Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin. Infect. Dis. (2004) 38:426-429.
   PubMed Web of Science ®Google Scholar
• KRAFT WK, MCCREA JB, WINCHELL GA et al.: Indinavir and rifabutin drug interactions in healthy volunteers. J. Clin. Pharmacol. (2004) 44:305-313.
   PubMed Web of Science ®Google Scholar
• CARR A, SAMARAS K, BURTON S et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12:F51-F58.
   PubMed Web of Science ®Google Scholar
• TSIODRAS S, MANTZOROS C, HAMMER S et al.: Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch. Intern. Med. (2000) 160:2050-2056.
   PubMed Web of Science ®Google Scholar
• HENRY K, MELROE H, HUEBESCH J et al.: Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet (1998) 352:1031-1032.
   PubMed Web of Science ®Google Scholar
• LENNERNAS H, FAGER G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. (1997) 32:403-425.
   PubMed Web of Science ®Google Scholar
• FICHTENBAUM CJ, GERBER JG: Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. (2002) 41:1195-1211.
   PubMed Web of Science ®Google Scholar
• FICHTENBAUM CJ, GERBER JG, ROSENKRANZ SL et al.: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (2002) 16:569-577.
   PubMed Web of Science ®Google Scholar
• ABERG JA, ROSENKRANZ SL, FICHTENBAUM CJ et al.: Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS (2006) 20:725-729.
   PubMed Web of Science ®Google Scholar
• BARRY M, BELZ G, ROLL S et al.: Interaction of nelfinavir with atorvastatin and pravastatin in normal healthy volunteers [Abstract P260]. 5th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (22 – 26 October 2000).
   Google Scholar
• HSYU PH, SCHULTZ-SMITH MD, LILLIBRIDGE JH et al.: Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob. Agents Chemother. (2001) 45:3445-3450.
   PubMed Web of Science ®Google Scholar
• COOPER KJ, MARTIN PD, AARON L: Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br. J. Clin. Pharmacol. (2002) 55:94-99.
   Web of Science ®Google Scholar
• BARRY M: Rosuvastatin–warfarin drug interaction. Lancet (2004) 36:328.
   Google Scholar
• GERBER JG, FICHTENBAUM CJ, ROSENKRANZ SL et al.: Efavirenz (EFV) is a significant inducer of simvastatin (SIM) and atorvastatin (ATR) metabolism: results of ACTG A5108 study. 2nd IAS Conference on Pathogenesis and Treatment of HIV. Paris, France (13 – 16 July 2003).
   Google Scholar
• CASTRO JG, GUTIERREZ L: Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine [letter]. Am. J. Med. (2002) 112:505.
   PubMed Web of Science ®Google Scholar
• GERBER JG, ROSENKRANZ SL, FICHTENBAUM CJ: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune. Defic. Syndr. (2005) 39:307-312.
   PubMed Web of Science ®Google Scholar
• RODRIGUES D, ROBERTS EM, MULFORD DJ et al.: Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the Cytochrome P4503A (CYP3A) subfamily. Drug Metab. Disp. (1997) 25:623-630.
   PubMed Web of Science ®Google Scholar
• GRUB S, BRYSON H, GOGGIN T et al.: The interaction of saquinavir(soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur. J. Clin. Pharmacol. (2001) 57:115-121.
   PubMed Web of Science ®Google Scholar
• BROPHY DF, ISRAEL DS, PASTOR A et al.: Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob. Agents Chemother. (2000) 44:978-984.
   PubMed Web of Science ®Google Scholar
• OUELLET D, HSU A, GRANNEMAN GR et al.: Pharmacokinetic interaction between ritonavir and clarithromycin. Clin. Pharmacol. Ther. (1998) 64:355-362.
   PubMed Web of Science ®Google Scholar
• AMSDEN GW, NAFZIGER AN, FOULDS G et al.: A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J. Clin. Pharmacol. (2000) 40:1522-1527.
   PubMed Web of Science ®Google Scholar
• SAHAI J, GALLICANO K, OLIVERAS L et al.: Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin. Pharmacol. Ther. (1993) 53:292-297.
   PubMed Web of Science ®Google Scholar
• POLIS MA, PISCITELLI SC, VOGEL S et al.: Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob. Agents Chemother. (1997) 41:1709-1714.
   PubMed Web of Science ®Google Scholar
• PISCITELLI SC, KELLY G, WALKER RE et al.: A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (1999) 43:647-650.
   PubMed Web of Science ®Google Scholar
• MOORE KH, YUEN GJ, RAASCH RH et al.: Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin. Pharmacol. Ther. (1996) 59:550-558.
   PubMed Web of Science ®Google Scholar
• POLK RE, CROUCH MA, ISREAL DS et al.: Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy (1999) 19:1378-1384.
   PubMed Web of Science ®Google Scholar
• KHALIQ Y, GALLICANO K, VENANCE S et al.: Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. (2000) 68:637-646.
   PubMed Web of Science ®Google Scholar
• CATO A, CAO G, HSU A et al.: Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab. Dispos. (1997) 25:1104-1106.
   PubMed Web of Science ®Google Scholar
• DE WIT A, DEBIER M, DESMET M et al.: Effect of fluconazole on indinavir pharmacokinetics in human deficiency virus-infected patients. Antimicrob. Agents Chemother. (1999) 43:432-433.
   PubMedGoogle Scholar
• JACKSON KA, ROSENBAUM SE, KERR BM et al.: A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a Phase III clinical trial. Antimicrob. Agents Chemother. (2000) 44:1832-1837.
   PubMed Web of Science ®Google Scholar
• KOKS CHW, CROMMENTUYN KML, HOETELMANS RMW et al.: The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br. J. Clin. Pharmacol. (2001) 51:631-635.
   PubMed Web of Science ®Google Scholar
• WIT SDE, SMET MDE, MCCREA J et al.: Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (1998) 42:223-227.
   PubMed Web of Science ®Google Scholar
• LAMSON M, ROBINSON P, GIGLIOTTI M et al.: The pharmacokinetic (PK) interactions of nevirapine (NVP) and ketoconazole (Keto). 12th World AIDS Conference. Geneva, Switzerland, (Jun 29 – July 3 1998): Abstract 12218.
   Google Scholar
• SRIWIRIYAJAN S, MAHATTHANATRAKUL W, RIDTITID W et al.: Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. Eur. J. Clin. Pharmacol. (2007) 63:479-483.
   PubMed Web of Science ®Google Scholar
• JARURATANASIRIKUL S, SRIWIRIYAJAN S: Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur. J. Clin. Pharmacol. (2007) 63:451-456.
   PubMed Web of Science ®Google Scholar
• LIU P, FOSTER G, LABADIE R et al.: Pharmacokinetic interaction between voriconazole and ritonavir at steady state in healthy subjects. Clin. Pharmacol. Ther. (2004) 77:P40.
   Google Scholar
• ROSSELLI M, DUBEY RK: Estrogen metabolism and reproduction – is there a relationship? J. Fertilität. Reprod. (2006) 16:19-23.
   Google Scholar
• MILDVAN D, YARRISH R, MARSHAK A et al.: Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J. Acquir. Immune. Defic. Syndr. (2002) 29:471-477.
   PubMed Web of Science ®Google Scholar
• OUELLET D, HSU A, QIAN J et al.: Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br. J. Clin. Pharmacol. (1998) 46:111-116.
   PubMed Web of Science ®Google Scholar
• SINICCO A, RAITERI R, ROSSATI A et al.: Efavirenz interference in estradiol ELISA assay. Clin. Chem. (2000) 46:734-735.
   PubMed Web of Science ®Google Scholar
• MALATY LI, KUPER JJ: Drug interactions of HIV protease inhibitors. Drug Saf. (1999) 20:147-169.
   PubMed Web of Science ®Google Scholar
• TABURET AM, SINGLAS E: Drug interactions with antiviral drugs. Clin. Pharmacokinet. (1996) 30:385-401.
   PubMed Web of Science ®Google Scholar
• RAGNI MV, DODSON SF, HUNT SC et al.: Liver transplantation in hemophilia patients with acquired immunodeficiency syndrome. Blood (1999) 93:1113-1115.
   PubMed Web of Science ®Google Scholar
• SCHVARCZ R, RUDBECK G, SODERDAHL G et al.: Interaction between nelfinavir and tacrolimus after orthotopic liver transplantation in a patient not infected with HIV and hepatitis C virus (HCV). Transplantation (2000) 69:2194-2195.
   PubMed Web of Science ®Google Scholar
• SHEIKH AM, WOLF DC, LEBOVICS E et al.: Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation (1999) 68:307-309.
   PubMed Web of Science ®Google Scholar
• TSENG A, NGUYEN ME, CARDELLA C et al.: Probable interaction between efavirenz and cyclosporine. AIDS (2002) 16:505-506.
   PubMed Web of Science ®Google Scholar
• ASHOK KUMAR BJ, VENKATARAMANAN R, FRIDELL JA et al.: The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transplant. (2002) 8:841-845.
   PubMed Web of Science ®Google Scholar
• ASHOK KUMAR BJ, VENKATARAMANAN R, FRIDELL JA et al.: Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transplant. (2002) 8:838-840.
   PubMed Web of Science ®Google Scholar
• BRINKMAN K, HUYSMANS F, BURGER DM: Pharmacokinetic interaction between saquinavir and cyclosporine. Ann. Intern. Med. (1998) 129:914-915.
   PubMed Web of Science ®Google Scholar
• FRASSETTO L, THAI T, AGGARWAL AM et al.: Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab. Pharmacokinet. (2003) 18:114-120.
   PubMedGoogle Scholar
• BOFFITO M, CARRIERO P, TRENTINI L et al.: Pharmacokinetics of saquinavir co-administered with cimetidine. J. Antimicrob. Chemother. (2002) 50:1081-1084.
   PubMed Web of Science ®Google Scholar
• BURGER DM, HUGEN PWH, KROON FP et al.: Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS (1998) 12:2080-2082.
   PubMed Web of Science ®Google Scholar
• WARRINGTON JS, SHADER RI, VON MOLTKE LL et al.: In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab. Disp. (2000) 28:392-397.
   PubMed Web of Science ®Google Scholar
• MERRY C, BARRY MG, RYAN M et al.: Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS (1999) 13:S101-S107.
   PubMed Web of Science ®Google Scholar
• HALL MCS, AHMAD S: Interaction between sildenafil and HIV-1 combination therapy. Lancet (1999) 353:2071-2072.
   PubMed Web of Science ®Google Scholar
• MUIRHEAD GJ, WULFF MB, FIELDING A et al.: Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol. (2000) 50:99-107.
   PubMed Web of Science ®Google Scholar
• KRETH K, KOVAR K, SCHWAB M et al.: Identification of the human cytochromes P450 involved in the oxidative metabolism of “ecstasy”-related designer drugs. Biochem. Pharmacol. (2000) 59:1563-1571.
   PubMed Web of Science ®Google Scholar
• HENRY JA, HILL IR: Fatal interaction between ritonavir and MDMA. Lancet (1998) 352:1751-1752.
   PubMed Web of Science ®Google Scholar
• HARRINGTON RD, WOODWARD JA, HOOTON TM et al.: Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and γ-hydroxybutyrate. Arch. Intern. Med. (1999) 159:2221-2224.
   PubMed Web of Science ®Google Scholar
• IRIBARNE C, BERTHOU F, BAIRD S et al.: Involvement of cytochrome P450 3A4 enzyme in the N-demethyl ation of methadone in human liver microsomes. Chem. Res. Toxicol. (1996) 9:365-373.
   PubMed Web of Science ®Google Scholar
• HEELON MW, MEADE LB: Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy (1999) 19:471-472.
   PubMed Web of Science ®Google Scholar
• OTERO MJ, FUERTES A, SANCHEZ R et al.: Nevirapine induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS (1999) 13:1004-1005.
   PubMed Web of Science ®Google Scholar
• ALTICE FL, FRIEDLAND GH, COONEY EL: Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS (1999) 13:957-962.
   PubMed Web of Science ®Google Scholar
• PINZANNI V, FAUCHERRE V, PEYIERE H et al.: Methadone withdrawal symptoms with nevirapine and efavirenz. Ann. Pharmacother. (2000) 34:405-407.
   Google Scholar
• CLARKE SM, MULCAHY FM, TJIA J et al.: Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. (2001) 33:1595-1597.
   PubMed Web of Science ®Google Scholar
• CLARKE SM, MULCAHY FM, TJIA J: The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. (2000) 51:213-217.
   Web of Science ®Google Scholar
• MARZOLINI C, TROILLET N, TELENTI A et al.: Efavirenz decreases methadone blood concentrations. AIDS (2000) 14:1291-1292.
   PubMed Web of Science ®Google Scholar
• MCCANCE-KATZ EF, RAINEY PM, SMITH P: Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am. J. Addict. (2006) 15:23-34.
   PubMed Web of Science ®Google Scholar
• GERBER JG, ROSENKRANZ S, SEGAL Y et al.: Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J. AIDS (2001) 27:153-160.
   PubMed Web of Science ®Google Scholar
• BEAUVERIE P, TABURET A-M, DESSALLES M-C et al.: Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. AIDS (1998) 12:2510-2511.
   PubMed Web of Science ®Google Scholar
• GELETKO SM, ERICKSON AD: Decreased methadone effect after ritonavir initiation. Pharmacotherapy (2000) 20:93-94.
   PubMed Web of Science ®Google Scholar
• MCCANCE-KATZ EF, FARBER S, SELWYN PA et al.: Decrease in methadone levels with nelfinavir mesylate. Am. J. Psychiatry (2000) 157:481.
   PubMed Web of Science ®Google Scholar
• FARAGON JJ, PILIERO PJ: Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read. (2003) 13:433-450.
   PubMedGoogle Scholar
• BART PA, RIZZARDI PG, GALLANT S et al.: Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther. Drug Monit. (2001) 23:553-555.
   PubMed Web of Science ®Google Scholar
• HSU A, GRANNEMAN GR, WITT G et al.: Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. (1997) 41:898-905.
   PubMed Web of Science ®Google Scholar
• LUO G, CUNNINGHAM M, KIM S et al.: CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. (2002) 30:795-804.
   PubMed Web of Science ®Google Scholar
• LUO G, LIN J, FISKE WD et al.: Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab. Dispos. (2003) 31:1170-1175.
   PubMed Web of Science ®Google Scholar
• LUO G, GUENTHNER T, GAN L, HUMPHREYS WG et al.: CYP3A4 Induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr. Drug Metab. (2004) 5:483-505.
   PubMed Web of Science ®Google Scholar
• SHELTON MJ, CLOEN D, BERENSON C, ESCH A, BREWER J, HEWITT R: Pharmacokinetics of once daily saquinavir/ritonavir: effects on unbound methadone and α-acid glycoprotein. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial. Chicago, IL, USA, 16 – 19 December (2001):abstract A-492.
   Google Scholar
• PALKAMA VJ, AHONEN J, NEUVONEN PJ et al.: Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin. Pharmacol. Ther. (1999) 66:33-39.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS et al.: Alprazolam/ritonavir interaction: implications for product labeling. Clin. Pharmacol. Ther. (2000) 67:335-341.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, HARMATZ et al.: Differential impairment of triazolam and zolpidem clearance by ritonavir. J. AIDS (2000) 24:129-136.
   PubMed Web of Science ®Google Scholar
• MERRY C, MULCAHY F, BARRY M et al.: Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. AIDS (1997) 11:268-269.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, DAILY JP et al.: Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J. Clin. Psycho. Pharmacol. (1999) 19:293-296.
   PubMed Web of Science ®Google Scholar
• MOULY S, RIZZO-PADOIN N, SIMONEAU G et al.: Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. Br. J. Clin. Pharmacol. (2006) 62:200-209.
   PubMed Web of Science ®Google Scholar
• FELLAY J, MARZOLINI C, DECOSTERD L et al.: Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur. J. Clin. Pharmacol. (2005) 60:865-873.
   PubMed Web of Science ®Google Scholar
• CULM-MERDEK KE, VON MOLTKE LL, GAN L: Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin. Pharmacol. Ther. (2006) 79:243-254.
   PubMed Web of Science ®Google Scholar
• BHIGJEE AI: Seizures in HIV/AIDS: a southern African perspective. Acta Neurol. Scand. (2005) 112:4-7.
   Web of Science ®Google Scholar
• HUGEN PW, BURGER DM, BRINKMAN K et al.: Carbamazepine: indinavir interaction causes antiretroviral therapy failure. Ann. Pharmacother. (2000) 34:465-470.
   PubMed Web of Science ®Google Scholar
• GARCIA BA, IBARRA LA, ETESSAM PJ et al.: Protease inhibitor-induced carbamazepine toxicity. Clin. Pharmacol. (2000) 23:216-218.
   Google Scholar
• BURMAN W, ORR L: Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz. AIDS (2000) 14:2793-2794.
   PubMed Web of Science ®Google Scholar
• BATES DE, HERMAN RJ: Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann. Pharmacother. (2006) 40:1190-1195.
   PubMed Web of Science ®Google Scholar
• LIM ML, MIN SS, ERON JJ et al.: Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J. AIDS (2004) 36:1034-1040.
   PubMed Web of Science ®Google Scholar
• KOMITI A, JUDD F, GRECH P et al.: Depression in people living with HIV/AIDS attending primary care and outpatients clinics. Aust. NZ J. Psychiatry (2003) 37:70-77.
   PubMed Web of Science ®Google Scholar
• RABKIN J: Prevalence of psychiatric disorders in HIV illness. Int. Rev. Psychiatry (1996) 8:157.
   Web of Science ®Google Scholar
• AASS N, FOSSA SD, DAHL AA et al.: Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. Eur. J. Cancer (1997) 33:1597-604.
   PubMed Web of Science ®Google Scholar
• SPINA E, POLLICINO AM, AVENOSO A et al.: Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther. Drug Monit. (1993) 15:243-246.
   PubMed Web of Science ®Google Scholar
• ALFARO CL, LAM YW, SIMPSON J et al.: CYP2D6 status of extensive metabolizers following multiple dose fluvoxamine, fluoxetine, sertraline, or paroxetine. J. Clin. Psychopharmacol. (1999) 19:155-163.
   PubMed Web of Science ®Google Scholar
• BOTTS SR, ALFARO C: Antidepressant drug interactions. J. Pharm. Pract. (2001) 14:467-477.
   Google Scholar
• DESILVA KE, LE FLORE DB, MARSTON BJ et al.: Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS (2001) 15:1281-1285.
   PubMed Web of Science ®Google Scholar
• OUELLET D, HSU A, QIAN J et al.: Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob. Agents Chemother. (1998) 42:3107-3112.
   PubMed Web of Science ®Google Scholar
• TSENG AL, FOISY MM: Significant interactions with new antiretrovirals and psychotropic drugs. Ann. Pharmacother. (1999) 33:461-473.
   PubMed Web of Science ®Google Scholar
• ELLIOTT AJ, RUSSO J, BERGAM K et al.: Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J. Clin. Psychiatry (1999) 60:226-231.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS et al.: Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J. Clin. Pharmacol. (2003) 43:414.
   PubMed Web of Science ®Google Scholar
• FARAGON JJ, PURDY BD, PILIERO PJ: An assessment of herbal therapy use, adherence and pharmacy service utilization in outpatient HIV clinics. J. Herb. Pharmacother. (2002) 2:27-37.
   PubMedGoogle Scholar
• PISCITELLI SC, BURNSTEIN AH, CHAITT D et al.: Indinavir concentrations and St. John's wort. Lancet (2000) 355:547-548.
   PubMed Web of Science ®Google Scholar
• DE MAAT MMR, HOETELMANS RMW, MATHÔT RAA et al.: Drug interaction between St. Johns wort and nevirapine. AIDS (2001) 15:420-421.
   PubMed Web of Science ®Google Scholar
• FOSTER BC, FOSTER MS, VANDENHOEK S et al.: An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J. Pharm. Pharm. Sci. (2001) 4:176-184.
   PubMed Web of Science ®Google Scholar
• DALVI RR: Alterations in hepatic Phase I and Phase II biotransformation enzymes by garlic oil in rats. Toxicol. Lett. (1992) 60:299-305.
   PubMed Web of Science ®Google Scholar
• PISCITELLI SC, BURSTEIN AH, WELDEN N et al.: The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis (2002) 34:234-238.
   PubMed Web of Science ®Google Scholar
• EAGLING VA, PROFIT L, BACK DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. (1999) 48:543-552.
   PubMed Web of Science ®Google Scholar
• PENZAK SR, ACOSTA EP, TURNER M et al.: Effect of seville orange juice and grapefruit juice on indinavir pharmacokinetics. J. Clin. Pharmacol. (2002) 42:1165-1170.
   PubMed Web of Science ®Google Scholar
• SHELTON MJ, WYNN HE, HEWITT RG et al.: Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. J. Clin. Pharmacol. (2001) 41:435-442.
   PubMed Web of Science ®Google Scholar
• FUHR U: Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf. (1998) 18:251-272.
   PubMed Web of Science ®Google Scholar
• KUPFERSCHMIDT HHT, FATTINGER KE, HA HR et al.: Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. (1998) 45:355-359
   PubMed Web of Science ®Google Scholar
• OHYAMA K, NAKAJIMA M, NAKAMURA S et al.: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug. Metab. Disp. (2000) 28:1303-1310.
   PubMed Web of Science ®Google Scholar
• LOHMAN JJHM, REICHERT LJM, DEGEN LPM: Antiretroviral therapy increases serum concentrations of amiodarone. Ann. Pharmacother. (1999) 33:645-646.
   PubMed Web of Science ®Google Scholar
• ZHOU Q, YAO T, ZENG S: Chiral metabolism of propafenone in rat hepatic microsomes treated with two inducers. World J. Gastroenterol. (2001) 7:830-835.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL E, SALA F, CHICHMANIAN R-M et al.: Ergotism related to concurrent administration of ergotamine tartrate and indinavir [letter]. JAMA (1999) 281:987.
   PubMed Web of Science ®Google Scholar
• MORTIER E, POUCHOT J, VINCENEUX P et al.: Ergotism related to interaction between nelfinavir and ergotamine [letter]. Am. J. Med. (2001) 110:594.
   PubMedGoogle Scholar
• MONTERO A, GIOVANNONI AG, TVRDE PL: Leg ischemia in a patient receiving ritonavir and ergotamine. Ann. Intern. Med. (1999) 130:329-330.
   PubMed Web of Science ®Google Scholar
• LIAUDET L: Severe ergotism associated with interaction between ritonavir and ergotamine [letter]. BMJ (1999) 318:771.
   PubMed Web of Science ®Google Scholar
• YENI PG, HAMMER SM, CARPENTER CCJ et al.: Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 288:222-235.
   PubMed Web of Science ®Google Scholar
• LEE BL, TäUBER MG, SADLER B et al.: Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin. Pharmacol. Ther. (1996) 59:14-21.
   PubMed Web of Science ®Google Scholar
• KHALIQ Y, GALLICANO K, TISDALE C et al.: Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br. J. Clin. Pharmacol. (2001) 51:591-600.
   PubMed Web of Science ®Google Scholar
• GATTI G, ALESSANDRINI A, CAMERA M et al.: Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS (1998) 12:825-826.
   PubMed Web of Science ®Google Scholar
• DIONISIO D, MININNI S, BARTOLOZZI D et al.: Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS (2001) 15:277-278.
   PubMed Web of Science ®Google Scholar
• KNOELL KR, YOUNG TM, COUSINS ES: Potential interaction involving warfarin and ritonavir. Ann. Pharmacother. (1998) 32:1299-1302.
   PubMed Web of Science ®Google Scholar
• NEWSHAN G, TSANG P: Ritonavir and warfarin interaction. AIDS (1999) 13:1788-1789.
   PubMed Web of Science ®Google Scholar
• DARLINGTON MR: Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter]. Ann. Pharmacother. (1997) 31:647.
   PubMed Web of Science ®Google Scholar
• HSU A, GRANNEMAN GR, WITT G et al.: Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. 11th International Conference on AIDS, Vancouver (BC), Canada (7 – 12 July 1996): Abstract Mo.B.1200.
   Google Scholar
• PISCITELLI SC, VOGEL S, FIGG WD et al.: Alteration of indinavir clearance during interleukin-2 infusions in patients infected with the immunodeficiency virus. Pharmacotherapy (1998) 19:1212-1216.
   Google Scholar
• HAAS CE, KAUFMAN DC, JONES CE et al.: Cytochrome P4503A4 activity after surgical stress. Crit. Care Med. (2003) 31:1338-1346.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-NOVOA S, BARREIRO P, ANA RENDO'N A et al.: Influence of 516G1T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. (2005) 40:1358-1361.
   PubMed Web of Science ®Google Scholar
• RAKHMANINA NY, VAN DEN ANKER JN, SOLDIN SJ: Drug monitoring of antiretroviral therapy. AIDS Patient Care and STDs (2004) 18:7-14.
   PubMed Web of Science ®Google Scholar

Websites

• http://www.cdc.gov/tb/TB_HIV_Drugs/Table1.htm CDC website, Division Tuberculosis Elimination. TB/HIV Drug Interactions (January 2004).
   Google Scholar
• http://www.hiv-druginteractions.org ARV drug interactions web site by The University of Liverpool (2007).
   Google Scholar
• http://medicine.iupui.edu/flockhart/table.htm P450 tables website (2006).
   Google Scholar
• http://www.who.int/mediacentre/factsheets/fs165/en/ WHO website, Fact sheet N°165. Epilepsy: etiology, epidemiology and prognosis (2001).
   Google Scholar
• http://www.hiv-pharmacogenomics.org The pharmacogenetic HIV database website, by The University of Liverpool (2007).
   Google Scholar